Citations

Showing 10 of 108104 citations.

Prognostic role of myocardial inflammation in patients with undefined left ventricular arrhythmogenic cardiomyopathy
Peretto, G, Merlo, M, Benedetti, S, Cappelletto, C, Casari, G, Sala, S, Sinagra, G, Bella, P Della, Casella, Michela , Merlo, M, Cappelletto, C, Rizzo, Stefania , Russo, A Dello, Basso, Cristina , Sinagra, G, Cooper, Leslie T.

Mayo Clinic

EP Europace | May 19, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euac053.545 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background Etiology identification and risk stratification represent major issues for patients presenting with undefined left ventricular arrhythmogenic cardiomyopathy (ULVACM). Purpose To investigate the role of genetics and histology for ULVACM classification, management, and risk assessment. Methods We retrospectively analyzed a multicenter cohort of patients (screened n=1037) with ULVACM defined by ventricular arrhythmia (VA) onset, nonischemic late gadolinium enhancement (LGE) limited to the LV, and no severe dilated cardiomyopathy (LVEF≥40%). We selected patients undergoing both next generation sequencing (NGS) screening and endomyocardial biopsy (EMB) for etiology definition. When feasible, immunosuppressive therapy (IST) was used to target active myocardial inflammation (AMI). The study endpoint was a composite of cardiac death, heart transplantation and malignant VAs (VT, VF, appropriate ICD treatment). Results The study cohort is composed by 135 ULVACM patients (age 43±14 years, 63% males, LVEF 55±7 %). NGS identified pathogenic or likely-pathogenic variants (PVs/LPVs) consistent with ACM in 21 cases (16%), whereas EMB showed AMI in 78 patients (58%), including 13/21 PVs/LPVs+ (62%). After reclassification of 86 patients (64%), only 49 (36%) remained ULVACM. IST was started in 41/78 AMI patients (53%), including 9/13 PVs/LPVs+ (69%). Twenty patients (15%) met the study endpoint by 12 months, and 36 (27%) by the end of the study (60±27 months). Beyond malignant VT onset, AMI was the only predictor of events by 12 months (HR 5.0, 95%CI 1.4-18.1, p=0.007). No prognostic role was found for PVs/LPVs, except for the subgroup (n=77) with nonsustained VT onset. Among AMI patients, those treated by IST had a significantly lower occurrence of events, both by 12-months (1/41 vs. 16/37, p<0.001) and later (HR 0.05, 95%CI 0.01-0.21, p<0.001). Results were independently confirmed in PVs/LPVs+ and PVs/LPVs- cases. Excluding the IST population, the association of multiple factors among VT onset, PVs/LPVs, and AMI, resulted in an improved discrimination of arrhythmic risk profiles. Conclusion The combined genetic and histological workup allowed reclassification of up to 64% ULVACM patients, and substantially contributed into prognostic assessment. Furthermore, EMB identified suitable candidates for IST, who showed better outcomes irrespectively of their genotype.
The prevalence of Type-1 Brugada pattern in African American: a large population study from the United States
Fatunde, Olubadewa A. , Ko, N Ko, Shen, W, Sorajja, Dan , Rattanawong, Pattara , Ko, Nway L. Ko

Mayo Clinic

EP Europace | May 19, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euac053.334 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background The prevalence of Type-1 Brugada pattern in Caucasians and Asians have been estimated to be 20 and 180 per 100,000. However, the prevalence of Type-1 Brugada pattern in African Americans has never been studied. Purpose This study aims to identify the prevalence of Type-1 Brugada pattern in African Americans. Methods Medical records of African American patients ages 18 years old or older with at least one 12-lead electrocardiogram (ECG) performed at 16 hospitals from 5 states in a single healthcare system between January 1, 2011 to December 31, 2020 were included. The search engine software was used to identify patients with keywords (Brugada pattern, Brugada ECG, Brugada Type-1, or Brugada syndrome) documented in the electronic medical record. The 12-lead ECGs were retrospectively analyzed by 2 cardiologists. Any inconsistencies were reviewed by a third cardiac electrophysiologist. Type-1 Brugada pattern was diagnosed according to the recent Heart Rhythm Society Expert Consensus Statement. Results Among 43,116 African American patients, (46.9% males), 6 patients (mean age 44.8±13.9 years, 100% males) had Type-1 Brugada pattern documented on at least one 12-lead ECG. The prevalence of Type-1 Brugada pattern in this large patient population of African American was 13.9 per 100,000. None of the patients had major arrhythmic event at 6.7±4.7 years follow-up. Conclusions The prevalence of Type-1 Brugada pattern in African American is lower than Caucasian and Asian populations. The risk of major arrhythmic event of Type-1 Brugada pattern in African American appears to be low; however longer follow-up data is needed.
Selective epicardial pulsed field ablation of atrial ganglionated plexi causes anti-arrhythmic prolongation of refractoriness: demonstration of feasibility in cardiac surgery patients
Groot, JR De , Shaburishvili, Tamaz, Zyl, Martin van , Brien, B O, Reilly, J, Coffey, Kaley A, Neuzil, P., Reddy, VY, Skalský, Ivo , Reilly, John

Mayo Clinic

EP Europace | May 19, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euac053.227 Get It

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): EU Horizon 2020 SME Instrument. Background Epicardial ganglionated plexi (GP) play a significant role in the initiation and maintenance of atrial fibrillation. However, modulation of this effect, through GP ablation, has had limited success; outcomes being confounded by unnecessary atrial tissue ablation and inability to access and ablate all of the atrial GPs. Selective pulsed field ablation (PFA) of GPs, using epicardial access, provides the opportunity to better identify the role of GP ablation in the treatment of atrial fibrillation. Purpose This study aimed to assess the safety and feasibility of selective GP ablation in patients undergoing elective coronary artery bypass grafting (CABG). It was hypothesized that GP ablation would provide an acute extension of atrial tissue refractoriness, which constitutes its antiarrhythmic effect. Methods Using a monopolar, monophasic PFA system, atrial GPs were ablated in nineteen patients with or without atrial fibrillation, undergoing CABG. The Oblique Sinus GP, Right Superior GP, Transverse Sinus GP, Left Superior GP and Ligament of Marshall GP were each ablated with up to sixty PFA pulses of 1000 V amplitude and 100 µs pulse width. Atrial Effective Refractory Period (AERP) was measured before and after all GP ablations, at the left atrial appendage (LAA) and on the right atrium (RA). Patients were monitored through to discharge for post-operative atrial fibrillation (POAF). Results Complete ablation of the GPs was performed in nineteen patients (aged 63.4 ± 6.6 years, 63.1% male) immediately after sternotomy. Electric field pulses were ECG-gated, with energy delivery during the ventricular refractory period. All GP sites were successfully accessed and ablated; all patients progressed immediately to their planned elective surgery and were discharged on schedule. Procedure time, for all GP ablations and AERP measurements was in the range 35-45 minutes. Thirteen valid pre- and post-ablation datasets were obtained. AERP (LAA and RA combined) increased upon GP ablation on average by 23% (220 ± 46 ms pre-ablation versus 269 ± 59 ms post-ablation, p = 0.002). Four patients experienced POAF; there was no evident correlation between POAF and AERP data. Only three of the enrolled patients had a prior history of AF; none of these exhibited AF on 24-hour Holter monitoring at 3-month follow-up. Conclusions Selective epicardial PFA of GPs is feasible and safe. An acute increase in atrial tissue refractoriness is promising but further studies are required to see how this translates to longer term outcomes in symptomatic AF patients and in a percutaneous epicardial access setting.
A (modifiable) way to better Hodgkin lymphoma survivorship?
Cerhan, James R. , Cerhan, James R

Mayo Clinic

Blood | May 19, 2022 | Volume: 139 | Issue: 20 | Pages: 3004-3005

10.1182/blood.2021014856 | PMID 35587870 Get It

P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy
Wanhainen, Kelsey M. , Peng, Changwei , Zhou, Maggie H. , Macedo, Bruna de Gois , O’Flanagan, Stephen D. , Yang, Tingyuan , Kelekar, Ameeta , Silva, Henrique Borges da , Jameson, Stephen C. , O'Flanagan, Stephen , Burbach, Brandon J , Borges da Silva, Henrique , Jameson, Stephen C , Macedo, Bruna Gois

Mayo Clinic

Cancer Immunology Research | May 19, 2022 | Volume: 10 | Issue: 7 | Pages: 871-884

10.1158/2326-6066.cir-21-0691 | PMID 35588154 Get It

Abstract Expression of the purinergic receptor P2RX7 by CD8+ T cells promotes the generation of memory populations following acute infections. However, data suggest that P2RX7 may limit the efficacy of antitumor responses. Herein, we show that P2RX7 is beneficial for optimal melanoma control in a mouse CD8+ T-cell adoptive transfer model. Tumor-specific P2rx7–/– CD8+ T cells exhibited impaired mitochondrial maintenance and function but did not display signs of overt exhaustion early in the antitumor response. However, as the tumor burden increased, the relative frequency of P2RX7-deficient CD8+ T cells declined within the tumor; this correlated with reduced proliferation, increased apoptosis, and mitochondrial dysfunction. Extending these studies, we found that the transient in vitro stimulation of P2RX7 using the ATP analogue BzATP led to enhanced B16 melanoma control by CD8+ T cells. These findings are in keeping with the concept that extracellular ATP (eATP) sensing by P2RX7 on CD8+ T cells is required for their ability to efficiently eliminate tumors by promoting mitochondrial fitness and underscore the potential for P2RX7 stimulation as a novel therapeutic treatment to enhance tumor immunotherapy.
Physicians’ Experiences With Mistreatment and Discrimination by Patients, Families, and Visitors and Association With Burnout
Sinsky, Christine A. , Trockel, Mickey , Tutty, Michael , Satele, Daniel , Carlasare, Lindsey E. , Shanafelt, Tait D. , Dyrbye, Liselotte N. , Shanafelt, Tait D , West, Colin P.

Mayo Clinic

JAMA Network Open | May 19, 2022 | Volume: 5 | Issue: 5 | Pages: e2213080

10.1001/jamanetworkopen.2022.13080 | PMID 35587344 Get It

Bilateral Refractory Neurosensory Retinal and Pigment Epithelial Detachments
Houghton, Odette M.

Mayo Clinic

JAMA Ophthalmology | May 19, 2022 | Volume: 140 | Issue: 8 | Pages: 829

10.1001/jamaophthalmol.2022.0275 | PMID 35588351 Get It

An 88-year-old woman with a history of exudative age-related macular degeneration presents with persistent subretinal fluid and enlarging pigment epithelial detachments. What would you do next?
American Board of Orthopaedic Surgery’s Initiatives Toward Competency-Based Education
Heest, Ann E. Van , Bednar, Michael S., Carpenter, James E. , Garvin, Kevin L. , Harrast, John J. , Martin, David , Murray, Peter M. , Peabody, Terrance D. , Saltzman, Charles L. , Saniei, Mona , Taitsman, Lisa A. , Marsh, J. Lawrence , Van Heest, Ann , Armstrong, April D , Carpenter, James E , Garvin, Kevin L , Harrast, John J , Martin, David F , Murray, Peter M , Peabody, Terrance D , Saniei, Mona , Taitsman, Lisa A , Marsh, J Lawrence

Mayo Clinic

JBJS Open Access | May 19, 2022 | Volume: 7 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.21.00150 | PMID 35620526 Get It

Abstract The American Board of Orthopaedic Surgery (ABOS) is the national organization charged with defining education standards for graduate medical education in orthopaedic surgery. The purpose of this article is to describe initiatives taken by the ABOS to develop assessments of competency of residents to document their progress toward the independent practice of orthopaedic surgery and provide feedback for improved performance during training. These initiatives are called the ABOS Knowledge, Skills, and Behavior Program. Web-based assessment tools have been developed and validated to measure competence. These assessments guide resident progress through residency education and better define the competency level by the end of training. The background and rationale for these initiatives and how they serve as steps toward competency-based education in orthopaedic residency education in the United States will be reviewed with a vision of a hybrid of time and competency-based orthopaedic residency education that will remain 5 years in length, with residents assessed using standardized tools.
Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study
Kim, Soungmun, Jeong, Seogsong , Park, Sun Jae , Chang, Jooyoung , Choi, Seulggie , Cho, Yoosun , Ahn, Joseph , Lee, Gyeongsil , Son, Joung Sik , Ahn, Joseph C , Chang, Jooyoung , Park, Sang Min

Mayo Clinic

Journal of Clinical Medicine | May 19, 2022 | Volume: 11 | Issue: 10 | Pages: 2865

10.3390/jcm11102865 | PMID 35628991 Get It

(1) Background: The association between proton pump inhibitor (PPI) use and hepatocellular carcinoma (HCC) has been controversial, especially in the general population. We aimed to determine the impact of PPI on HCC risk in participants without liver cirrhosis or chronic hepatitis virus infection. (2) Methods: We assessed 406,057 participants from the Korean National Health Insurance Service database who underwent health screening from 2003 to 2006. We evaluated exposure to PPI before the index date using a standardized daily defined dose (DDD) system. The association of proton pump inhibitor use with the risk of HCC was evaluated using multivariable-adjusted Cox proportional hazards regression. (3) Results: Compared with non-users, PPI use was not associated with the HCC risk in low (<30 DDDs; aHR, 1.07; 95% CI, 0.91–1.27), intermediate (30 ≤ PPI < 60 DDDs; aHR, 0.96; 95% CI, 0.73–1.26), and high (≥60 DDDs; aHR, 0.86; 95% CI, 0.63–1.17) PPI groups in the final adjustment model. In addition, risks of cirrhosis-associated HCC and non-cirrhosis-associated HCC were not significantly associated with PPI use. The results remained consistent after excluding events that occurred within 1, 2, and 3 years to exclude pre-existing conditions that may be associated with the development of HCC. We also found no PPI-associated increase in HCC risk among the selected population, such as those with obesity, older age, and chronic liver diseases. (4) Conclusions: PPI use may not be associated with HCC risk regardless of the amount. We call for future studies conducted in other regions to generalize our findings.
Diaphragm muscle function in a mouse model of early-onset spasticity
Fogarty, Matthew J. , Brandenburg, Joline E. , Zhan, Wen‐Zhi, Sieck, Gary C. , Sieck, Gary , Fogarty, Matthew J

Mayo Clinic

Journal of Applied Physiology | May 19, 2022 | Volume: 133 | Issue: 1 | Pages: 60-68

10.1152/japplphysiol.00157.2022 | PMID 35608200 Get It

Developmental motor control dysfunctions, including spastic cerebral palsy (sCP) often have respiratory components. Spa mutant mice exhibit a spastic phenotype closely resembling sCP symptoms. Using the spa mouse model of spastic cerebral palsy (sCP), we quantified transdiaphragmatic pressure deficits, diaphragm muscle weakness, and fiber type-specific atrophy, improving our understanding of respiratory dysfunctions in sCP.